Abstract
This review describes gene therapy strategies that take advantage of defective signal transduction pathways to selectively kill cancer cells without adversely affecting normal cells. The distinctive features of cancer cells currently exploited by gene therapy include mitosis, cell permissiveness to infection, specific protease activity, and the activity of the p53, Rb / E2F and wnt / catenin signal transduction pathways. In most cases, proof of concept has been obtained in vitro and in vivo, but only a few approaches made it to the clinic. Overall, the clinical success rate has been disappointing and it is concluded that the gene therapy of cancer requires more innovation and hard work before its potential can be fully realized.
Keywords: cancer cells, gene therapy strategies, proliferation, susceptibility to infection, protease activity, oncolytic adenoviruses
Current Pharmaceutical Design
Title: Gene Therapy Approaches for the Selective Killing of Cancer Cells
Volume: 8 Issue: 19
Author(s): Eva Maria Westphal and Harald von Melchner
Affiliation:
Keywords: cancer cells, gene therapy strategies, proliferation, susceptibility to infection, protease activity, oncolytic adenoviruses
Abstract: This review describes gene therapy strategies that take advantage of defective signal transduction pathways to selectively kill cancer cells without adversely affecting normal cells. The distinctive features of cancer cells currently exploited by gene therapy include mitosis, cell permissiveness to infection, specific protease activity, and the activity of the p53, Rb / E2F and wnt / catenin signal transduction pathways. In most cases, proof of concept has been obtained in vitro and in vivo, but only a few approaches made it to the clinic. Overall, the clinical success rate has been disappointing and it is concluded that the gene therapy of cancer requires more innovation and hard work before its potential can be fully realized.
Export Options
About this article
Cite this article as:
Westphal Maria Eva and von Melchner Harald, Gene Therapy Approaches for the Selective Killing of Cancer Cells, Current Pharmaceutical Design 2002; 8 (19) . https://dx.doi.org/10.2174/1381612023393927
DOI https://dx.doi.org/10.2174/1381612023393927 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Arsenic-exposed Keratinocytes Exhibit Differential microRNAs Expression Profile; Potential Implication of miR-21, miR-200a and miR-141 in Melanoma Pathway
Clinical Cancer Drugs Therapy Based on the Regulation of Thiol-dependent Redox Systems
Current Medicinal Chemistry Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Current Pharmaceutical Design Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets Application of Baculovirus-Insect Cell Expression System for Human Therapy
Current Pharmaceutical Biotechnology Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Nanoparticle-Delivered Quercetin for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Microarray Data Analysis: Current Practices and Future Directions
Current Pharmacogenomics Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters Current Status of Delivery Systems to Improve Target Efficacy of Oligonu-cleotides
Current Pharmaceutical Design G-Quadruplex Interacting Agents Targeting the Telomeric G-Overhang Are More than Simple Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells
Anti-Cancer Agents in Medicinal Chemistry The Peripheral Anionic Site of Acetylcholinesterase: Structure, Functions and Potential Role in Rational Drug Design
Current Pharmaceutical Design Identification of Small Molecule Sulfonic Acids as Ecto-5'-Nucleotidase Inhibitors
Medicinal Chemistry Resistance to Peloruside A and Laulimalide: Functional Significance of Acquired βI-tubulin Mutations at Sites Important for Drug-Tubulin Binding
Current Cancer Drug Targets